$0.85
0.49% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US44148G1058
Symbol
HOTH
Sector
Industry

Hoth Therapeutics, Inc. Stock price

$0.85
+0.07 9.63% 1M
+0.02 2.32% 6M
+0.10 13.06% YTD
-0.35 29.51% 1Y
-9.99 92.19% 3Y
-84.15 99.00% 5Y
-212.40 99.60% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.00 0.49%
ISIN
US44148G1058
Symbol
HOTH
Sector
Industry

Key metrics

Market capitalization $11.17m
Enterprise Value $-120.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.01
P/B ratio (TTM) P/B ratio 0.97
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-9.64m
Free Cash Flow (TTM) Free Cash Flow $-8.04m
Cash position $11.32m
EPS (TTM) EPS $-1.15
P/E forward negative
Short interest 1.10%
Show more

Is Hoth Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Hoth Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Hoth Therapeutics, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Hoth Therapeutics, Inc.:

Buy
100%

Financial data from Hoth Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.89 4.89
7% 7%
-
- Research and Development Expense 4.74 4.74
57% 57%
-
-9.63 -9.63
28% 28%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.64 -9.64
28% 28%
-
Net Profit -9.62 -9.62
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hoth Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hoth Therapeutics, Inc. Stock News

Neutral
PRNewsWire
9 days ago
HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis. Treatment shows potent downregulation of oncogenic KIT mutations with no observed systemic toxicity.
Neutral
PRNewsWire
about one month ago
Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK , April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by t...
Neutral
PRNewsWire
about one month ago
Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 in Open-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced Skin Toxicities Key Interim Results (Day 1–21): Patients experienced a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21. Rapid symptom relief was observed, with mean scores...
More Hoth Therapeutics, Inc. News

Company Profile

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.

Head office United States
CEO Robbie Knie
Employees 6
Founded 2017
Website www.hoththerapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today